Search clinical trials for: RRMS

Total 169 results

Novartis Pharmaceuticals

Not yet recruiting

ITAKOS - Italian Observation, Multicenter, Prospective Study of Ofatumumab in RRMS Patients

Multiple Sclerosis, Relapsing-Remitting
IRCCS San Raffaele

Recruiting

RRMS: Disease PROgression and Myeloid Profiling After Bone Marrow TRANSPLANTation and Second Line Therapies (TRANSPLANTPRO)

Multiple Sclerosis

Italy
Juno Therapeutics, Inc., a Bristol-Myers Squibb...
Celgene Corporation

Recruiting

A Study to Evaluate the Safety, Tolerability, Efficacy, and Drug Levels of CC-97540 in Participants With Relapsing Forms of Multiple Sclerosis or Progressive Forms of Multiple Sclerosis

Multiple Sclerosis

United States, Belgium, France, Germany, Spain, United Kingdom, Italy
Biogen

Recruiting

A Study to Assess New Participant's Perspectives Beyond Clinical Efficacy of Monoclonal Antibody-Based Relapsing Remitting Multiple Sclerosis (RRMS) Treatments

Multiple Sclerosis, Relapsing-Remitting

United States
Bristol-Myers Squibb

Recruiting

A Study to Describe the Persistence With Ozanimod Treatment in Relapsing-Remitting Multiple Sclerosis (RRMS) Participants (AppreZiate)

Relapsing-remitting Multiple Sclerosis (RRMS)

Spain
Bristol-Myers Squibb

Recruiting

A Study to Describe the Switching From a First- or Second-line Disease Modifying Therapy (DMT) to Ozanimod in Participants With Relapsing Remitting Multiple Sclerosis (RRMS) (SWITCH - ITA)

Multiple Sclerosis, Relapsing-Remitting

Italy
Assistance Publique - Hôpitaux de Paris

Recruiting

Multimodal Imaging Signatures of the Biological Mechanisms Underlying Neurodegeneration in Multiple Sclerosis (IMAGINDEALinMS)

Multiple Sclerosis (MS)

France
Cairo University

Not yet recruiting

Evaluation of the Proximal Contact Quality in Posterior Complex Carious Cavities Restored With Bulk Fill Ormocer and Resin Composite Using a Precontoured Circumferential Matrix System Versus Pre Contoured Sectional Matrix System

Posterior Complex Carious Proximal Cavities

Egypt
University Hospital of Mont-Godinne
Saint-Luc University Hospital

Recruiting

Multiparametric Assessment to Investigate Prognostic Factors for Disease Evolution a nd Evolutionary Patterns of Cognitive Status in RRMS (COGNIT-MS)

Multiple Sclerosis, Relapsing-Remitting

Belgium
Biogen

Recruiting

A Study for Tysabri Participant Preference

Relapsing-Remitting Multiple Sclerosis (RRMS)

Germany
Neuromed IRCCS
University of Rome Tor Vergata

Not yet recruiting

Effects of Ozanimod on Immune-mediated Mechanisms of Neurodegeneration in Multiple Sclerosis - a Preclinical Study

Healthy | Neuromyelitis Optica | Relapsing-Remitting Multiple Sclerosis (RRMS)

Italy
University Hospital, Bordeaux

Not yet recruiting

3D OPTIMIZED WMN MPRAGE Increased Detection of Focal Spinal Cord Lesion in Multiple Sclerosis (WHINUME) (WHINUME)

Multiple Sclerosis

France
University Hospital, Basel, Switzerland
Swiss National Science Foundation

Recruiting

Imaging the Interplay Between Axonal Damage and Repair in Multiple Sclerosis (INsIDER)

Multiple Sclerosis (MS) | Relapsing-remitting Multiple Sclerosis (RRMS) | Secondary-progressive Multiple Sclerosis (SPMS) | Primary Progressive Multiple Sclerosis (PPMS)

Switzerland
Novartis Pharmaceuticals

Recruiting

Efficacy and Safety of Remibrutinib Compared to Teriflunomide in Participants With Relapsing Multiple Sclerosis (RMS) (REMODEL-2)

Relapsing Multiple Sclerosis

United States, Canada, China, Spain, Italy, France, Slovenia, Japan, Turkey, Argentina, Estonia, Greece, Mexico, Poland, Sweden, Croatia, South Africa, Brazil, Slovakia, Bulgaria, Romania, India, Portugal, Puerto Rico, United Kingdom
Novartis Pharmaceuticals

Recruiting

Efficacy and Safety of Remibrutinib Compared to Teriflunomide in Participants With Relapsing Multiple Sclerosis

Relapsing Multiple Sclerosis

United States, China, Spain, Switzerland, Italy, Belgium, Latvia, Poland, Argentina, India, Croatia, Bulgaria, Malaysia, Slovakia, Lebanon, Guatemala, Netherlands, Colombia, Chile, United Kingdom, Denmark, Hong Kong, Ireland
Novartis Pharmaceuticals

Recruiting

A Multicenter Study of Continued Current Therapy vs Transition to Ofatumumab After Neurofilament (NfL) Elevation (SOSTOS)

Relapsing-Remitting Multiple Sclerosis

United States, Canada
Novartis Pharmaceuticals

Recruiting

Study to Assess the Effect of Ofatumumab in Treatment Naïve, Very Early RRMS Patients Benchmarked Against Healthy Controls. (AGNOS)

Relapse Remitting Multiple Sclerosis

United States, Puerto Rico
Brigham and Women's Hospital
Massachusetts General Hospital

Recruiting

Novel Assessment of Synaptic Density in Progressive MS

Multiple Sclerosis | Relapsing Multiple Sclerosis | Primary Progressive Multiple Sclerosis | Secondary Progressive Multiple Sclerosis

United States
Wayne State University

Recruiting

Investigating the Effect of Ocrelizumab in African Americans and Caucasians With Relapsing Multiple Sclerosis

Multiple Sclerosis, Relapsing-Remitting

United States
Riley Bove, MD

Recruiting

Bazedoxifene Acetate as a Remyelinating Agent in Multiple Sclerosis (ReWRAP)

Multiple Sclerosis | Multiple Sclerosis, Relapsing-Remitting

United States
Kessler Foundation

Recruiting

Evaluation of a Theory-Driven Manualized Approach to Improving New Learning and Memory in MS (STEM)

Multiple Sclerosis

United States
University Hospital, Strasbourg, France
Bayer; Grünenthal GmbH; Fédération Hospitalo-Universitaire NEUROGENYCS

Recruiting

TOTEM RRMS : TestOsterone TreatmEnt on Neuroprotection and Myelin Repair in Relapsing Remitting Multiple Sclerosis (TOTEM-RRMS)

Multiple Sclerosis, Relapsing-Remitting

France
M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Recruiting

Quizartinib, Decitabine, and Venetoclax in Treating Participants With Untreated or Relapsed Acute Myeloid Leukemia or High Risk Myelodysplastic Syndrome

Acute Myeloid Leukemia | Myelodysplastic Syndrome | Recurrent Acute Myeloid Leukemia | Recurrent Myelodysplastic Syndrome | Refractory Acute Myeloid Leukemia

United States
The Cleveland Clinic
University of Nottingham

Recruiting

Determining the Effectiveness of earLy Intensive Versus Escalation Approaches for RRMS (DELIVER-MS)

Multiple Sclerosis, Relapsing-Remitting

United States, United Kingdom
Haukeland University Hospital

Recruiting

Randomized Autologous heMatopoietic Stem Cell Transplantation Versus Alemtuzumab, Cladribine or Ocrelizumab for RRMS (RAM-MS) (RAM-MS)

Multiple Sclerosis

Norway, Sweden, Denmark, Netherlands
Bosnalijek D.D
MonitorCRO

Recruiting

A Phase IIIb, Multicenter, International Study to Evaluate the Efficacy, Safety and Tolerability of EK-12 in Patients With RRMS

Multiple Sclerosis, Relapsing-Remitting

Turkey
Biogen

Terminated

A Study to Investigate the Radiological Onset of Action After Treatment Initiation With Subcutaneous (SC) Natalizumab in Participants With Relapsing-Remitting Multiple Sclerosis (RRMS)

Multiple Sclerosis, Relapsing-Remitting

Germany
Novartis Pharmaceuticals

Active, not recruiting

A Single Arm Study Evaluating the Efficacy, Safety and Tolerability of Ofatumumab in Patients With Relapsing Multiple Sclerosis (OLIKOS)

Relapsing Multiple Sclerosis

United States, Puerto Rico
Hope Biosciences Stem Cell Research Foundation

Active, not recruiting

Randomized Double-Blind Phase 2 Efficacy and Safety of Autologous HB-MSCs vs Placebo for Treatment of Multiple Sclerosis (HBMS01)

Multiple Sclerosis

United States
Biogen

Completed

A Study to Evaluate Efficacy, Safety, and Tolerability of EID of Natalizumab (BG00002) in Participants With RRMS Switching From Treatment With Natalizumab SID in Relation to Continued SID Treatment- Followed by Extension Study Comprising SC and IV Natalizumab Administration

Multiple Sclerosis, Relapsing-Remitting

United States, Spain, Canada, Australia, Germany, Italy, United Kingdom, Belgium, Netherlands, France, Israel
Mapi Pharma Ltd.

Active, not recruiting

Safety, Tolerability and Efficacy of Monthly Long-acting IM Injection of 80 or 40 mg GA Depot in Subjects With RRMS

Multiple Sclerosis

Israel
Scripps Health

Withdrawn

Optimal Conditioning Regimen for Autologous Transplantation of Relapsing Remitting Multiple Sclerosis

Multiple Sclerosis, Relapsing-Remitting

United States
Hoffmann-La Roche

Completed

Study to Evaluate the Effectiveness and Safety of Ocrelizumab in Participants With Early Stage Relapsing Remitting Multiple Sclerosis (RRMS)

Multiple Sclerosis, Relapsing-Remitting

United States, United Kingdom, Australia, Belgium, Brazil, Croatia, France, Canada, Slovakia, Germany, Netherlands, Norway, Italy, Poland, Switzerland, Romania, Bulgaria, Spain, Mexico, Austria, Portugal, Turkey, Sweden, Argentina, Denmark and more
Genzyme, a Sanofi Company

Active, not recruiting

A Study to Evaluate Efficacy, Safety, and Tolerability of Alemtuzumab in Pediatric Patients With RRMS With Disease Activity on Prior DMT (LemKids)

Multiple Sclerosis

Portugal, Turkey, Italy, Austria, Belgium, France, Netherlands, Poland, Russian Federation, United Kingdom
Haukeland University Hospital
Oslo University Hospital; University Hospital of North Norway; Helse Stavanger... and other collaborators

Active, not recruiting

Ocrelizumab VErsus Rituximab Off-Label at the Onset of Relapsing MS Disease (OVERLORD-MS)

Relapsing Remitting Multiple Sclerosis

Norway, Sweden
Biogen

Completed

Plegridy Satisfaction Study in Participants (PLATINUM)

Relapsing-Remitting Multiple Sclerosis (RRMS)

Italy
Bayer

Completed

Evaluation of Potential Predictors of Adherence by Investigating a Representative Cohort of Multiple Sclerosis (MS) Patients in Germany Treated With Betaferon (BETAPREDICT)

Multiple Sclerosis

Germany
Biogen

Active, not recruiting

A Study Utilising Data From European Union (EU) National Multiple Sclerosis (MS) Registries to Assess the Incidence of Anti-Natalizumab Antibody Among Participants Who Receive Subcutaneous Administration of Natalizumab for Treatment of Relapsing-remitting Multiple Sclerosis (RRMS)

Multiple Sclerosis

United States
Polpharma Biologics S.A.

Completed

Efficacy and Safety of the Biosimilar Natalizumab PB006 in Comparison to Tysabri® (Antelope)

Relapsing-Remitting Multiple Sclerosis (RRMS)

Belarus, Ukraine, Georgia, Croatia, Moldova, Republic of, Poland, Serbia
Biogen

Active, not recruiting

Phase 3 Efficacy and Safety Study of BG00012 in Pediatric Subjects With Relapsing-remitting Multiple Sclerosis (RRMS) (CONNECT)

Relapsing-Remitting Multiple Sclerosis

Italy, Belgium, United States, Hungary, Sweden, United Kingdom, Israel, France, Czechia, Poland, Serbia, Denmark, Spain, Turkey, Bulgaria, Germany, Canada, Kuwait
George Washington University

Completed

Assessment of Deep Gray Matter Anatomic Changes in RRMS Patients Treated With Gilenya® With and Without Cognitive Impairment Over a 2 Year Period Using NeuroQuant, NeuroQuarc and ANAM (NeuroQuant)

Multiple Sclerosis, Relapsing-Remitting

United States
University of Michigan

Completed

Mechanistic Studies of Teriflunomide in RRMS

Relapsing Remitting Multiple Sclerosis

United States
Icahn School of Medicine at Mount Sinai

Withdrawn

Sensation, Motion, and Quality of Life on Natalizumab and Off Natalizumab

Relapsing-remitting Multiple Sclerosis (RRMS)

United States
Alexandria University

Completed

Lubiprostone for Functional Constipation in the Under 18 Years Patients

Drug Side Effect | Treatment Efficacy | Clinical Efficacy

Egypt
Assiut University

Completed

Lesion Load and Location in Relation to Cognition, Fatigue and Physical Disability in RRMS

Relapsing Remitting Multiple Sclerosis

Egypt
Cinnagen

Completed

Efficacy and Safety of Xacrel® (Ocrelizumab) in Participants With Relapsing Remitting Multiple Sclerosis

Multiple Sclerosis | Relapsing-Remitting

Iran, Islamic Republic of
Cinnagen

Completed

Efficacy and Safety of Peginterferon Beta-1a (CinnaGen) in Participants With Relapsing Remitting Multiple Sclerosis

Relapsing Remitting Multiple Sclerosis (RRMS)

Iran, Islamic Republic of
Biogen
Alkermes, Inc.

Completed

A Study of ALKS 8700 in Adults With Relapsing Remitting Multiple Sclerosis (MS) EVOLVE-MS-1

Multiple Sclerosis

United States, Bulgaria, Poland, Belgium, Canada, Germany, Russian Federation, Serbia, Spain, Ukraine
Boston Scientific Corporation

Terminated

A Study of Orally Administered BGC20-0134 (Structured Lipid) in Patients With Relapsing Remitting Multiple Sclerosis (RRMS)

Relapsing Remitting Multiple Sclerosis

Spain, Germany, Belgium, Poland, France, Russian Federation
Teva Branded Pharmaceutical Products R&D, Inc.

Completed

BRAVO Study: Laquinimod Double-blind Placebo-controlled Study in Participants With Relapsing-Remitting Multiple Sclerosis (RRMS) With a Rater Blinded Reference Arm of Interferon β-1a (Avonex®) (BRAVO)

Multiple Sclerosis

United States, Bulgaria, Croatia, Czechia, Estonia, Georgia, Germany, Israel, Italy, Lithuania, North Macedonia, Poland, Puerto Rico, Romania, Russian Federation, Slovakia, South Africa, Spain, Ukraine

Search clinical trials for: RRMS

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Iran

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations